Drugs / LINVENCORVIR
LINVENCORVIR
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT04729309 | Mar → Jun 2021 | — | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT03717064 | Nov → Dec 2018 | — | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT03570658 | Aug 2018 → Jan 2019 | hepatitis B virus infection | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT02952924 | Dec 2016 → Mar 2022 | chronic hepatitis B virus infection | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04225715 | Jul 2020 → Jul 2024 | chronic hepatitis B virus infection | Hoffmann-La Roche | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LINVENCORVIR | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095071 ↗ |
| Known as | RG-7907 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095071 ↗ |
| Known as | RO7049389 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03570658 ↗ |
| Action | Inhibit | “RO7049389, an inhibitor of hepatitis B virus (HBV) capsid assembly” PMID 32839221 ↗ Oct 2020 |
| Modality | Small molecule | — CHEMBL5095071 ↗ |
| Route | Oral | “RO7049389 will be administered orally either as a single dose (SAD) or as multiple doses defined by the SAD portion of the study (MAD).” NCT03570658 ↗ |